サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：複数がん早期発見の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- タイプ別、最終用途別、地域別、企業別
市場調査レポート
商品コード
1389857

複数がん早期発見の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- タイプ別、最終用途別、地域別、企業別

Multi-Cancer Early Detection Market - Global Multi-cancer Early Detection Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Type Coverage, By End User Coverage, By Geographic Coverage and By Company)

出版日
ページ情報
英文 157 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
複数がん早期発見の世界市場 - 世界の業界分析、規模、シェア、成長、動向、地域別見通し、予測（2023年～2030年）- タイプ別、最終用途別、地域別、企業別
出版日: 2023年11月27日
発行: Fairfield Market Research
ページ情報: 英文 157 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の複数がん早期発見（MCED）の市場規模は大幅に拡大する勢いであり、2023年から2030年のCAGRは16.3％になると予測されています。同市場は、2022年の約8億9,000万米ドルから、2030年末までに約25億米ドルまで拡大すると予測されています。

MCED市場は、がん罹患率の増加や、がんの早期発見に重点を置く政府の取り組みなどの要因別拡大するとみられます。様々ながんの兆候を正確かつ同時に検索できる検査の開拓が市場成長を促進すると予測されます。これらの検査は、多くの種類のがんに対する効率的なスクリーニングアプローチの欠如に対処するものです。

患者の生存率を高め、治療費を削減するための早期がん発見の利点に対する認識の高まりが、市場の可能性を後押ししています。2022年には、遺伝子パネルのカテゴリーがMCED市場を独占しました。遺伝子パネルは、さまざまな悪性腫瘍に関連する複数の遺伝子の標的研究を提供することで、正確なリスク評価と早期発見を可能にします。

当レポートでは、世界の複数がん早期発見市場について調査し、市場の概要とともに、タイプ別、最終用途別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の複数がん早期発見市場の見通し、2018年～2030年

  • 世界の複数がん早期発見市場の見通し、タイプ別、金額別（10億米ドル）、2018年～2030年
  • 世界の複数がん早期発見市場の見通し、最終用途別、金額（10億米ドル）、2018年～2030年
  • 世界の複数がん早期発見市場の見通し、地域別、金額（10億米ドル）、2018年～2030年

第4章 北米の複数がん早期発見市場の見通し、2018年～2030年

第5章 欧州の複数がん早期発見市場の見通し、2018年～2030年

第6章 アジア太平洋の複数がん早期発見市場の見通し、2018年～2030年

第7章 ラテンアメリカの複数がん早期発見市場の見通し、2018年～2030年

第8章 中東・アフリカの複数がん早期発見市場の見通し、2018年～2030年

第9章 競合情勢

  • 能力と用途のヒートマップ
  • メーカーと用途のヒートマップ
  • 企業の市場シェア分析、2022年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Grail, LLC
    • Illumina, Inc.
    • Exact Sciences Corporation
    • Foundation Medicine
    • AnchorDx
    • Guardant Health, Inc.
    • Burning Rock Biotech Limited
    • GENECAST
    • Laboratory for Advanced Medicine, Inc
    • Singlera Genomics Inc
    • Elypta
    • Prenetics Global Limited (Prenetics)
    • Oncocyte Corporation
    • Micronoma Inc
    • EarlyDiagnostics, Inc

第10章 付録

目次

The global multi-cancer early detection (MCED) market is on the verge of substantial expansion, with Fairfield Market Research projecting a notable CAGR of 16.3% between 2023 and 2030. The market, which reached a valuation of approximately $0.89 billion in 2022, is anticipated to soar to around $2.5 billion by the end of 2030.

Key Market Trends

  • 1. Rising Incidence of Cancer and Government Emphasis: The MCED market is set to expand due to factors such as the increasing incidence of cancer and government initiatives focusing on early cancer detection.
  • 2. Development of Precise Tests: The development of tests that can precisely and simultaneously search for signs of various cancers is projected to fuel market growth. These tests address the lack of efficient screening approaches for many types of cancer.
  • 3. Growing Awareness: Increased awareness of the benefits of early cancer detection for enhancing patient survival and lowering treatment costs is driving market potential.
  • 4. Gene Panels Dominate: In 2022, the gene panel category dominated the MCED market. Gene panels enable precise risk assessment and early detection by offering targeted studies of multiple genes associated with various malignancies.

Key Growth Determinants

Exploding Cancer Prevalence: The growing prevalence of cancer is a major driver of market demand. Chronic diseases like cancer disproportionately affect the elderly population, particularly in high-income countries. The market is expected to rise as the elderly population increases.

Awareness Initiatives: Rising government initiatives to increase public awareness of the benefits of early diagnosis will drive market growth for MCED. These initiatives aim to educate people about the need for early diagnosis, leading to increased demand for multi-cancer screening tests.

Benefits of Early Detection: Early cancer detection results in better treatment outcomes, lower healthcare expenditures, and higher patient survival rates. Prompt intervention and specialized therapy made possible by early diagnosis lead to better patient outcomes, encouraging investment in MCED technologies.

Major Barriers

High Diagnostic System Costs: High costs of diagnostic devices, stringent regulatory regulations, and lengthy clearance processes for new launches hinder global MCED market growth.

Adoption of Refurbished Imaging Systems: Hospitals in poorer countries, unable to invest in new diagnostic imaging technology, often opt for refurbished systems. These systems are more affordable than new ones, impacting market growth.

Regional Highlights

Europe Leads in Revenue Contribution: Europe's dominance is due to rising cancer incidence and increased investment in research and development. The region's expanding population, vulnerability to chronic diseases, and economic diagnosis in rural areas support market expansion.

North America Shows Fastest Growth: North America is expected to experience the fastest growth due to government and market participant activities. The region's expanding cancer incidence and significant trials further boost market growth.

Competitive Landscape Analysis

The global MCED market is consolidated, with a few significant companies operating worldwide. Major firms are launching new products and expanding their distribution networks to increase their global presence. Market consolidation is expected to continue in the coming years.

Leaders in Global Multi-Cancer Early Detection Space

  • 1. Grail, Llc
  • 2. Illumina, Inc.
  • 3. Exact Sciences Corporation
  • 4. Foundation Medicine, Inc.
  • 5. AnchorDx
  • 6. Guardant Health, Inc.
  • 7. Burning Rock Biotech Limited
  • 8. GENECAST
  • 9. Laboratory for Advanced Medicine, Inc.

10. Singlera Genomics Inc.

11. Elypta

12. Prenetics Global Limited (Prenetics)

13. Oncocyte Corporation

14. Micronoma Inc.

15. EarlyDiagnostics, Inc.

Global Multi Cancer Early Detection Market is Segmented as Below:

By Type:

  • Liquid Biopsy
  • Gene Panel
  • LDT
  • Others

By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Others

By Geographic Coverage:

  • North America

U.S.

Canada

  • Europe

Germany

U.K.

France

Italy

Turkey

Russia

Rest of Europe

  • Asia Pacific

China

Japan

South Korea

India

Southeast Asia

Rest of Asia Pacific

  • Latin America

Brazil

Mexico

Argentina

Rest of Latin America

  • Middle East & Africa

GCC

South Africa

Egypt

Nigeria

Rest of Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Multi Cancer Early Detection Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 3.1. Global Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Liquid Biopsy
      • 3.1.1.2. Gene Panel
      • 3.1.1.3. LDT
      • 3.1.1.4. Others
  • 3.2. Global Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospitals
      • 3.2.1.2. Diagnostic Laboratories
      • 3.2.1.3. Others
  • 3.3. Global Multi Cancer Early Detection Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 4.1. North America Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Liquid Biopsy
      • 4.1.1.2. Gene Panel
      • 4.1.1.3. LDT
      • 4.1.1.4. Others
  • 4.2. North America Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospitals
      • 4.2.1.2. Diagnostic Laboratories
      • 4.2.1.3. Others
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 4.3.1.2. U.S. Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 4.3.1.3. Canada Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 4.3.1.4. Canada Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 5.1. Europe Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Liquid Biopsy
      • 5.1.1.2. Gene Panel
      • 5.1.1.3. LDT
      • 5.1.1.4. Others
  • 5.2. Europe Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospitals
      • 5.2.1.2. Diagnostic Laboratories
      • 5.2.1.3. Others
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.2. Germany Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.3. U.K. Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.4. U.K. Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.5. France Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.6. France Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.7. Italy Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.8. Italy Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.9. Turkey Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.10. Turkey Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.11. Russia Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.12. Russia Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 5.3.1.13. Rest of Europe Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.3.1.14. Rest of Europe Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Liquid Biopsy
      • 6.1.1.2. Gene Panel
      • 6.1.1.3. LDT
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospitals
      • 6.2.1.2. Diagnostic Laboratories
      • 6.2.1.3. Others
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.2. China Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 6.3.1.3. Japan Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.4. Japan Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 6.3.1.5. South Korea Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.6. South Korea Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 6.3.1.7. India Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.8. India Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 6.3.1.9. Southeast Asia Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.10. Southeast Asia Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 6.3.1.11. Rest of Asia Pacific Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.3.1.12. Rest of Asia Pacific Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 7.1. Latin America Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Liquid Biopsy
      • 7.1.1.2. Gene Panel
      • 7.1.1.3. LDT
      • 7.1.1.4. Others
  • 7.2. Latin America Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospitals
      • 7.2.1.2. Diagnostic Laboratories
      • 7.2.1.3. Others
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.3.1.2. Brazil Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 7.3.1.3. Mexico Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.3.1.4. Mexico Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 7.3.1.5. Argentina Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.3.1.6. Argentina Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 7.3.1.7. Rest of Latin America Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.3.1.8. Rest of Latin America Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Multi Cancer Early Detection Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Liquid Biopsy
      • 8.1.1.2. Gene Panel
      • 8.1.1.3. LDT
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Diagnostic Laboratories
      • 8.2.1.3. Others
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Multi Cancer Early Detection Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.3.1.2. GCC Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 8.3.1.3. South Africa Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.3.1.4. South Africa Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 8.3.1.5. Egypt Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.3.1.6. Egypt Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 8.3.1.7. Nigeria Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.3.1.8. Nigeria Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
      • 8.3.1.9. Rest of Middle East & Africa Multi Cancer Early Detection Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.3.1.10. Rest of Middle East & Africa Multi Cancer Early Detection Market by End Use, Value (US$ Bn), 2018 - 2030
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Capacity vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Grail, LLC
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Illumina, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Exact Sciences Corporation
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Foundation Medicine
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. AnchorDx
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Guardant Health, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Burning Rock Biotech Limited
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. GENECAST
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Laboratory for Advanced Medicine, Inc
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Business Strategies and Development
    • 9.5.10. Singlera Genomics Inc
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Elypta
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Prenetics Global Limited (Prenetics)
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Oncocyte Corporation
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Micronoma Inc
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. EarlyDiagnostics, Inc
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations